Intellia Therapeutics (NTLA) Expected to Announce Quarterly Earnings on Thursday

Intellia Therapeutics (NASDAQ:NTLA) is expected to be issuing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Intellia Therapeutics to post earnings of ($0.99) per share and revenue of $12.1730 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 12:30 PM ET.

Intellia Therapeutics Trading Up 2.1%

NTLA opened at $12.48 on Thursday. Intellia Therapeutics has a 12 month low of $5.90 and a 12 month high of $28.25. The business’s 50-day moving average price is $11.29 and its 200-day moving average price is $12.93. The company has a market cap of $1.45 billion, a P/E ratio of -2.92 and a beta of 2.10.

Insider Buying and Selling at Intellia Therapeutics

In other Intellia Therapeutics news, EVP Birgit C. Schultes sold 8,508 shares of the firm’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $9.21, for a total transaction of $78,358.68. Following the completion of the transaction, the executive vice president owned 98,533 shares of the company’s stock, valued at approximately $907,488.93. This trade represents a 7.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO John M. Leonard sold 34,146 shares of the business’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $314,484.66. Following the sale, the chief executive officer owned 1,013,339 shares in the company, valued at approximately $9,332,852.19. This trade represents a 3.26% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 53,051 shares of company stock valued at $488,600. 3.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Intellia Therapeutics

Hedge funds have recently bought and sold shares of the business. Benjamin Edwards Inc. increased its stake in shares of Intellia Therapeutics by 1.8% during the second quarter. Benjamin Edwards Inc. now owns 63,034 shares of the company’s stock valued at $591,000 after purchasing an additional 1,126 shares in the last quarter. Ameriprise Financial Inc. grew its stake in shares of Intellia Therapeutics by 13.9% in the 2nd quarter. Ameriprise Financial Inc. now owns 11,803 shares of the company’s stock worth $111,000 after buying an additional 1,443 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Intellia Therapeutics in the 3rd quarter worth approximately $30,000. Advisory Services Network LLC bought a new position in Intellia Therapeutics during the 3rd quarter valued at approximately $33,000. Finally, Northwestern Mutual Wealth Management Co. raised its stake in Intellia Therapeutics by 38.6% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 7,080 shares of the company’s stock valued at $122,000 after buying an additional 1,970 shares during the last quarter. Institutional investors own 88.77% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. KeyCorp set a $25.00 price target on Intellia Therapeutics in a research note on Wednesday, January 28th. Tudor Pickering set a $14.50 target price on shares of Intellia Therapeutics in a research note on Tuesday, October 28th. Barclays dropped their price target on shares of Intellia Therapeutics from $24.00 to $14.00 and set an “overweight” rating for the company in a research report on Friday, November 7th. Royal Bank Of Canada decreased their price objective on shares of Intellia Therapeutics from $14.00 to $9.00 and set a “sector perform” rating on the stock in a research report on Friday, November 7th. Finally, Chardan Capital lowered their price objective on shares of Intellia Therapeutics from $48.00 to $26.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Eight investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, Intellia Therapeutics presently has an average rating of “Hold” and an average target price of $17.48.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.